Outlook Therapeutics Q3 net loss narrows slightly as costs drop
OTLK•Q3 loss narrows as expenses fall
Outlook Therapeutics said its fiscal third-quarter net loss narrowed as operating expenses declined from the prior year, mainly because of lower research and development and selling, general and administrative costs.
The company reported a third-quarter loss per share of $0.15.
Europe expansion and post-quarter financing
Outlook Therapeutics said it continued to expand commercialization of LYTENAVA in Germany, Austria and the UK, with further launches planned in Europe.
After the quarter ended, the company raised $51.1 million in net proceeds from a public offering.
LYTENAVA launch plans and commercialization update
The U.S. biopharmaceutical company said it is advancing its U.S. launch strategy for LYTENAVA, its FDA-approved ophthalmic bevacizumab for wet AMD.
Outlook Therapeutics plans a U.S. launch by the end of calendar 2026 and estimates LYTENAVA annual U.S. sales could exceed $500 million by 2030. The company also said it plans to submit for a permanent HCPCS code by Oct. 1, 2026, to support reimbursement.
